2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle  
06/26/17AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CHICAGO, June 26, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at a price to the public of $70.00 per share before underwriting discounts and commissions, including 536,250 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares.  The net proceeds to AveXis from the offering, after deducting the underwriting discounts ... 
 Printer Friendly Version
06/20/17AveXis Announces Pricing of Public Offering of Common Stock
CHICAGO, June 20, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,575,000 shares of its common stock.  The net proceeds to AveXis from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by AveXis, are expected to be approximately $234.5 million.  The offering is expected to close on or about June 26, 2017, subject to customary closing conditions. In addition, Av... 
 Printer Friendly Version
06/19/17AveXis Announces Proposed Public Offering of Common Stock
CHICAGO, June 19, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $200 million of shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill Lynch are actin... 
 Printer Friendly Version
06/14/17AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101
– Agency is supportive of proposed analytical methods and comparability protocol – –  AveXis anticipates initiating U.S. SMA Type 1 and Type 2 trials in Q3 2017 with product from new process – –  AveXis manufacturing facility is fully operational for GMP product production – – Conference call and webcast today at 4:30 p.m. EDT – CHICAGO, June 14, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare... 
 Printer Friendly Version
06/07/17AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
REGENXBIO grants AveXis new licenses to NAV AAV9 vector for the development and commercialization of treatments for Rett syndrome (RTT) and amyotrophic lateral sclerosis (ALS) CHICAGO and ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and REGENXBIO Inc. (NASDAQ:RGNX) today announced an exclusive worldwide license agreement for AveXis to develop and commercialize gene therapy treatments using REGENXBIO’s NAV AAV9 vector to treat two rare neurological monogenic dis... 
 Printer Friendly Version
05/11/17AveXis Reports First Quarter 2017 Financial and Operating Results
– Conference call of April 25 was in lieu of Q1 2017 earnings call – CHICAGO, May 11, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the first quarter ended March 31, 2017, recent corporate highlights and upcoming milestones. “We are very pleased with our progress during the first quarter and recent weeks, ... 
 Printer Friendly Version
05/04/17AveXis to Report First Quarter 2017 Financial and Operating Results
Results to be reported on May 11, 2017 CHICAGO, May 04, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will report financial and operating results for the first quarter ended March 31, 2017, on Thursday, May 11, 2017, after the close of U.S.-based financial markets. Due to the recent conference call and webcast from the American Academy of N... 
 Printer Friendly Version
04/25/17AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
– 10 of 12 patients on proposed therapeutic dose sat unassisted; patient videos demonstrate motor milestone achievement not seen in natural history of disease – – 86% of patients without feeding support and 70% of patients without respiratory support prior to dosing continue without any support – – 92% of patients on proposed therapeutic dose fed orally – – Conference call and webcast April 25 at 4:30 p.m. EDT – BOSTON, April 25, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a cli... 
 Printer Friendly Version
04/18/17AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology
– Includes Results from Phase 1 Trial of AVXS-101 in SMA Type 1 – – Conference call and webcast Tuesday, April 25 at 4:30 p.m. EDT – CHICAGO, April 18, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will host a live webcast briefing of AVXS-101 data as presented at the 2017 Annual Meeting of the American Academy of Neurology in Boston, includi... 
 Printer Friendly Version
03/16/17AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
– No new treatment-related safety or tolerability findings – – No new events reported and 15 of 15 patients event-free at 13.6 months of age; majority of patients receiving proposed therapeutic dose sit unassisted – – Conference call and webcast March 16 at 4:30 p.m. EDT – CHICAGO, March 16, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic disea... 
 Printer Friendly Version
03/09/17AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017
-- Conference call and webcast on March 16 at 4:30 p.m. EDT -- CHICAGO, March 09, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce topline results from the Phase 1 clinical trial of AVXS-101 in patients with SMA Type 1, and financial and operating results for the fourth quarter and full year ended December 31, 2016 on Thursday, Ma... 
 Printer Friendly Version
03/02/17AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting
-- Key preclinical and clinical data of AVXS-101 in SMA to be presented -- CHICAGO, March 02, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced results from the Phase 1 trial of AVXS-101, AveXis’ proprietary gene therapy candidate for the treatment of spinal muscular atrophy (SMA) Type 1, will be presented at the 2017 Annual Meetin... 
 Printer Friendly Version
02/15/17AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer
CHICAGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the appointment of Rick Modi to the executive management team as Senior Vice President and Chief Business Officer. Mr. Modi brings more than 15 years of commercial, business, and corporate experience to the position, and is responsible for all aspects of the compan... 
 Printer Friendly Version
02/06/17AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients
Company provides update following receipt of Scientific Advice response from the EMA CHICAGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the planned pivotal study of AVXS-101 in spinal muscular atrophy (SMA) Type 1 in the European Union (EU) will reflect a single-arm design, using natural history of the disease... 
 Printer Friendly Version
01/31/17AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1
PRIME intended to optimize development and speed evaluation of AVXS-101 through enhanced interactions and early dialogue with EMA CHICAGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the European Medicines Agency (EMA) has granted access into its PRIority MEdicines (PRIME) program for the company’s proprietary g... 
 Printer Friendly Version
01/03/17AveXis to Present at the 35th Annual J.P. Morgan Healthcare Conference
CHICAGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced Sean Nolan, President and Chief Executive Officer, will present a corporate update at the 35th Annual J.P. Morgan Healthcare Conference at 5:00 p.m. PST, Monday, January 9, 2017, with a Q&A session to follow. A live, listen-only webcast of the presentation wi... 
 Printer Friendly Version
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet